Neurocrine Biosciences (NBIX) CLO Lippoldt Buys $16K of Stock

Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences, Inc. (NasdaqGS: NBIX), purchased 200 shares of the company on June 26, 2026. The shares were bought at an average price of $81.49, amounting to a total value of $16,298. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Neurocrine Biosciences, Inc.

Lippoldt's purchase on June 26 was followed by other transactions on June 29, where he sold 9,800 shares at an average price of $170.16 in a planned sale, and another 9,800 shares in an unplanned sale. These transactions reveal active trading activity by the executive in the days following his purchase.

Other Institutional Activity in Neurocrine Biosciences

Several institutional investors also made moves in Neurocrine Biosciences. BlackRock, Inc. added 555,010 shares, ending with 13,385,607 shares valued at approximately $1.76 billion, showing a 4.3% increase. Dodge & Cox trimmed its holdings by 47,005 shares, holding 5,461,037 shares worth about $719.4 million, reflecting a 0.9% decrease. JPMorgan Chase & Co. grew its stake by 241,711 shares, totaling 5,442,067 shares valued at $700.5 million, a 4.6% increase. AQR Capital Management LLC made a significant addition of 1,667,261 shares, bringing its total to 4,938,967 shares, a 51% increase, valued at $650.7 million. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 4,726,344 shares worth approximately $622.6 million.

Neurocrine Biosciences, Inc. Stock Up 24.1%

On Wednesday, shares of Neurocrine Biosciences traded near $170. The company boasts a market cap of $16.95 billion and a P/E ratio of 25.93. The stock's 52-week range is between $122.14 and $171.50, with a 50-day moving average of $151.83 and a 200-day moving average of $141.99. Neurocrine has a beta of 0.396, indicating lower volatility compared to the market. It maintains a current ratio of 2.929 and a quick ratio of 2.506, with a debt-to-equity ratio of 13.603.

Analysts Set New Price Targets

On June 2, 2026, Goldman Sachs reinstated its buy rating on Neurocrine Biosciences, setting a price target of $213. RBC Capital maintained its buy rating with a target of $183 on May 29, while Bernstein initiated coverage with a buy rating and a target of $221 on May 22. The consensus among 28 analysts is a strong buy, with a mean price target of $195.06.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc., based in San Diego, California, is a healthcare company specializing in the discovery, development, and commercialization of pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders. The company offers products like INGREZZA for tardive dyskinesia, Orilissa for endometriosis, and Oriahnn for uterine fibroids. Neurocrine also collaborates with several pharmaceutical companies to expand its product pipeline. Led by CEO Mr. Kyle W. Gano, Ph.D., the company employs around 2,000 people.

Bottom Line

Darin Lippoldt's recent purchase of Neurocrine Biosciences shares highlights insider confidence in the company. With a strong buy consensus from analysts and recent institutional interest, Neurocrine remains a company to watch. As always, remember that insider transactions and 13F filings are backward-looking and may not reflect current holdings or future performance.